Alere Reports Second Quarter 2017 Financial Results
WALTHAM, Mass., Aug. 3, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced its financial results for the second quarter ended June 30, 2017.
Second Quarter 2017
-- Total revenue was $558 million, a 9% decrease compared to $610 million
in the prior year period.
-- Non-GAAP organic growth during the second quarter of 2017 was -7.8% and
-3.6% excluding Arriva.*
-- Negative impact of foreign currency exchange was $6 million in the
second quarter of 2017.
-- GAAP loss from continuing operations during the second quarter of 2017
was $(93) million, or $(1.13) per diluted share, compared to $(33)
million, or $(0.44) per diluted share in the prior year period.
-- Non-GAAP adjusted EBITDA was $44 million in the second quarter of 2017,
compared to $91 million in the prior year period. The decrease was
primarily due to higher merger-related costs and audit and legal fees
related to ongoing investigations as detailed in the Supplemental
Financial Information table.
Six Months 2017
-- For the six months ended June 30, 2017, revenue was $1.15 billion, a 4%
decrease compared to $1.20 billion in the prior year period. The
decrease was primarily due to $28 million in Arriva products and
services revenue that could not be recognized (see note below*), and a
decrease in seasonal product sales. The Company also continued to make
investments in global operations and infrastructure to strengthen the
enterprise.
-- Non-GAAP organic growth during the six months ended June 30, 2017 was
-3.6% and +1.4% excluding Arriva.*
*During the three and six months ended June 30, 2017, the Company furnished to customers $14 million and $28 million, respectively, of Arriva products and services revenue and corresponding earnings that were subject to the CMS revocation but did not recognize any revenue for such products and services because they were not eligible for reimbursement by CMS at the time the Company furnished them.
Revenue (in millions) Second Second % Change
Quarter 2017
Quarter 2016
(as restated)
------------
Cardiometabolic Disease $140 $167 (16%)
Infectious Disease 167 189 (12%)
Toxicology 160 158 1%
Other 35 36 (4%)
Consumer Diagnostics 17 20 (17%)
Other Non-reportable* 37 37 1%
License and Royalty 3 3 18%
--- --- ---
Total $558 $610 (9%)
==== ==== ===
Certain amounts presented may not recalculate directly, due to rounding.
*Patient self-testing has been reclassified into a separate reporting segment called "Other Non-reportable."
Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses Non-GAAP adjusted EBITDA and Non-GAAP organic growth, which are non-GAAP financial measures. The reconciliations of Non-GAAP adjusted EBITDA to net income (loss) from continuing operations and Non-GAAP organic growth to revenue, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP, is shown in the table in this press release. The Company believes Non-GAAP adjusted EBITDA and Non-GAAP organic growth are useful to investors because these metrics are commonly used by investors to assess the unleveraged, pre-tax financial performance and operating results of our ongoing business operations. The Company's management also uses Non-GAAP adjusted EBITDA and Non-GAAP organic growth because the Company's management also believes that these are useful measures to evaluate operating performance and cash flows of the Company based on operational factors. It should also be noted that not all companies calculate Non-GAAP adjusted EBITDA and Non-GAAP organic growth in the same manner and, accordingly, these measures presented in this press release may not be comparable to similar measures used by other companies.
Conference Call
As announced on February 1, 2016, Alere entered into a definitive agreement under which Abbott will acquire Alere, which definitive agreement was amended on April 13, 2017. The transaction is expected to close by the end of the third quarter of 2017, subject to the satisfaction of certain customary closing conditions, including applicable regulatory approvals. Due to the pending transaction, Alere will no longer hold conference calls to discuss its quarterly financial results.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as "preliminary", "may," "could," "should," "would," "intend," "will," "expect," "anticipate," "believe," "estimate," "can," "continue" or similar words, and include statements with respect to the merger with Abbott Laboratories ("Abbott") expecting to close by the end of the third quarter of 2017. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott, and the divestitures of certain Alere businesses in connection therewith, may not be completed in a timely manner or at all; (ii) the possibility that competing offers or acquisition proposals for Alere will be made; (iii) the possibility that any or all of the various conditions to the consummation of the merger with Abbott (or the divestitures of certain Alere businesses in connection therewith) may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, as amended (the "Merger Agreement") among Alere and Abbott pursuant to which Abbott will acquire Alere, including in circumstances which would require Alere to pay a termination fee or other expenses; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreements to divest certain Alere businesses in connection with the merger with Abbott; (vi) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement or the divestiture of certain businesses on Alere's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (vii) risks related to diverting management's attention from Alere's ongoing business operations; (viii) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; (ix) the possibility that the previously announced review of certain aspects of revenue recognition uncovers an additional error or errors in revenue recognition or other financial information which require additional adjustments which may be material, or material weaknesses in the Company's internal controls over financial reporting; (x) risks relating to the ongoing investigations by the United States Securities and Exchange Commission (the "SEC") and the United States Department of Justice, and (xi) the risk factors detailed in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (as filed with the SEC on June 5, 2017) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
About Alere
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.(TM) Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.
Alere Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended June 30, Six Months Ended June 30,
2017 2016 (as restated) 2017 2016 (as restated)
---- ----------------- ---- -----------------
Net product sales and services revenue $554,691 $607,771 $1,140,265 $1,191,982
License and royalty revenue 2,981 2,533 5,623 5,262
----- ----- ----- -----
Net revenue 557,672 610,304 1,145,888 1,197,244
Cost of net revenue 304,940 328,666 611,430 644,481
------- ------- ------- -------
Gross profit 252,732 281,638 534,458 552,763
Gross margin 45% 46% 47% 46%
Operating expenses:
Research and development 29,448 28,446 55,732 55,508
Selling, general and administrative 252,283 239,298 512,747 454,894
Impairment and (gain) loss on disposition, net - - - (3,810)
Operating income (28,999) 13,894 (34,021) 46,171
Interest and other income (expense), net (47,710) (46,241) (93,409) (89,696)
------- ------- ------- -------
Loss from continuing operations before provision (benefit) for income taxes (76,709) (32,347) (127,430) (43,525)
Provision (benefit) for income taxes 17,312 2,582 35,921 2,410
------ ----- ------ -----
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (94,021) (34,929) (163,351) (45,935)
Equity earnings of unconsolidated entities, net of tax 1,321 2,122 6,522 7,156
----- ----- ----- -----
Income (loss) from continuing operations (92,700) (32,807) (156,829) (38,779)
Income from discontinued operations, net of tax - - - -
Net income (92,700) (32,807) (156,829) (38,779)
Less: Net income attributable to non-controlling interests 368 143 551 246
Net income attributable to Alere Inc. and Subsidiaries (93,068) (32,950) (157,380) (39,025)
Preferred stock dividends (5,308) (5,308) (10,558) (10,617)
Net income available to common stockholders $(98,376) $(38,258) $(167,938) $(49,642)
======== ======== ========= ========
Basic net income per common share:
Income (loss) from continuing operations $(1.13) $(0.44) $(1.92) $(0.57)
Income from discontinued operations - -
Basic and diluted net income per common share $(1.13) $(0.44) $(1.92) $(0.57)
Diluted net income per common share:
Income (loss) from continuing operations $(1.13) $(0.44) $(1.92) $(0.57)
Income from discontinued operations - - -
Diluted net income per common share $(1.13) $(0.44) $(1.92) $(0.57)
Weighted average shares - basic 87,360 86,737 87,300 86,692
====== ====== ====== ======
Weighted average shares - diluted 87,360 86,737 87,300 86,692
====== ====== ====== ======
Alere Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
June 30, December 31,
2017 2016
---- ----
ASSETS
------
CURRENT ASSETS:
Cash and cash equivalents $491,699 $567,215
Restricted cash 52,480 51,550
Marketable securities 150 76
Accounts receivable, net 377,963 413,535
Inventories, net 335,710 308,920
Prepaid expenses and other
current assets 125,604 118,607
Assets held for sale - -
Total current assets 1,383,606 1,459,903
Property, Plant and
Equipment, net 436,201 441,190
Goodwill and other
intangible assets, net 3,574,864 3,592,107
Restricted Cash- non-current 2,353 2,171
Other non-current assets 159,811 152,908
Assets held for sale - non-
current - -
--- ---
Total assets $5,556,835 $5,648,279
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Short-term debt and current
portions of long-term debt
and capital lease
obligations $86,671 $85,434
Liabilities related to
assets held for sale - -
Other current liabilities 592,768 590,722
Total current liabilities 679,439 676,156
------- -------
LONG-TERM LIABILITIES:
Long-term debt and capital
lease obligations, net of
current portions 2,820,775 2,865,426
Deferred tax liabilities 123,775 119,098
Other long-term liabilities 167,273 155,992
Liabilities related to
assets held for sale -
non-current - -
Total long-term liabilities 3,111,823 3,140,516
--------- ---------
TOTAL EQUITY 1,765,573 1,831,607
Total liabilities and equity $5,556,835 $5,648,279
========== ==========
Alere Inc. and Subsidiaries
Selected Consolidated Revenues
(in thousands)
Three Months Ended June 30, % Change
2017 2016 (as restated) 2017 v. 2016
---- ----------------- ------------
Professional diagnostics segment
Cardiometabolic $139,840 $167,378 -16%
Infectious disease 166,544 189,384 -12%
Toxicology 159,871 158,196 1%
Other 35,123 36,413 -4%
------ ------
Total professional diagnostics segment 501,378 551,371 -9%
Consumer diagnostics segment 16,507 19,794 -17%
Other Non-reportable 36,804 36,606 1%
License and royalty revenue 2,981 2,533 18%
----- -----
Net revenue $557,670 $610,304 -9%
===========
Six Months Ended June 30, % Change
2017 2016 (as restated) 2017 v. 2016
---- ----------------- ------------
Professional diagnostics segment
Cardiometabolic $265,017 $327,041 -19%
Infectious disease 389,478 381,339 2%
Toxicology 310,508 304,979 2%
Other 68,051 69,795 -2%
------ ------
Total professional diagnostics segment 1,033,054 1,083,154 -5%
Consumer diagnostics segment 33,747 37,236 -9%
Other Non-reportable 73,464 71,592 3%
License and royalty revenue 5,623 5,262 7%
----- -----
Net revenue $1,145,888 $1,197,244 -4%
===========
Alere Inc. and Subsidiaries
Reconciliation of Net Income (Loss) to Non-GAAP EBITDA
(in thousands)
Three Months Ended June 30,
2017 2016 (as restated)
---- -----------------
Net
Income
(loss)
(1) $(92,700) $(32,807)
Income
tax
provision
(benefit) 17,312 2,582
Depreciation
and
amortization 62,575 69,977
Interest,
net 45,044 41,684
Non-
cash
stock-
based
compensation
expense 9,568 11,004
Non-
cash
fair
value
adjustments
to
acquisition-
related
contingent
consideration 2,345 (1,923)
Non-
GAAP
Adjusted
EBITDA $44,144 $90,518
======= =======
(1) Net income (loss) for the three months ended June 30, 2016 includes $10.5 million of Abbott integration costs, $10.2 million for a legal settlement accrual, restructuring charges of $8.8 million, $5.1 million of charges related to governmental investigations, $0.1 million of costs associated with business dispositions, and $0.2 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The three months ended June 30, 2017 includes $26.1 million of Abbott integration costs, $15.9 million of charges related to governmental investigations, non-interest related restructuring charges of $2.6 million, expense related to the withdrawal of the InRatio product of ($2.6) million, $0.1 million of costs associated with business dispositions, and $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.
Six Months Ended June 30,
2017 2016 (as restated)
---- -----------------
Net Income
(loss) (1) $(156,829) $(38,779)
Income tax
provision
(benefit) 35,921 2,410
Depreciation and
amortization 123,558 142,588
Interest, net 87,243 82,625
Non-cash stock-
based
compensation
expense 19,932 20,606
Non-cash fair
value
adjustments to
acquisition-
related
contingent
consideration 2,833 (1,781)
Impairment and
(gain) loss on
dispositions,
net (229) (3,810)
Non-GAAP
Adjusted EBITDA $112,429 $203,860
======== ========
(1) Net income (loss) for the six months ended June 30, 2016 includes $20.9 million of Abbott integration costs, $19.6 million of charges related to governmental investigations, restructuring charges of $16.4 million, $0.9 million of costs associated with business dispositions, and $0.7 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The six months ended June 30, 2017 includes $67.5 million of Abbott integration costs, $26 million of charges related to governmental investigations, non-interest related restructuring charges of $5.7 million, expense related to the withdrawal of the InRatio product of ($2.6) million, $0.2 million of costs associated with business dispositions, and $0.2 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.
Alere Inc. and Subsidiaries
Reconciliation of Non-GAAP Organic Revenue Growth
(in thousands)
Three Months Ended June 30, % Change
2017 2016 (as restated) 2017 v. 2016
---- ----------------- ------------
Net revenue $557,670 $610,304 -8.6%
Impact of
foreign
currency
exchange 5,624 -
Impact of
acquisitions &
dispositions (775) -
---- ---
Non-GAAP
organic net
revenue $562,519 $610,304 -7.8%
======== ========
Arriva revenue (2,274) (29,065)
Non-GAAP
organic net
revenue
(excluding
Arriva) $560,245 $581,239 -3.6%
======== ========
Six Months Ended June 30, % Change
2017 2016 (as restated) 2017 v. 2016
---- ----------------- ------------
Net revenue $1,145,887 $1,197,244 -4.3%
Impact of
foreign
currency
exchange 10,393 -
Impact of
acquisitions &
dispositions (1,675) -
------ ---
Non-GAAP
organic net
revenue $1,154,605 $1,197,244 -3.6%
========== ==========
Arriva revenue (5,313) (64,208)
Non-GAAP
organic net
revenue
(excluding
Arriva) $1,149,292 $1,133,036 1.4%
========== ==========
Alere Inc. and Subsidiaries
Supplemental Financial Information
(in thousands, except per share amounts)
Three months ended June 30, 2017
--------------------------------
Cost of Net Research and Selling, General Impairment, Interest and Provision for Equity earnings of Net Income(1)
Revenue Development & net of loss on other income taxes unconsolidated entities,
Administrative disposition income, net net of tax
---
Amortization of acquisition-related intangible assets $11,193 $1,928 $23,776 $ - $ - $ - $ - $(36,897)
Restructuring charges 996 (13) 1,665 - - - - (2,648)
Impairment Charges - 2 - - - - - (2)
Stock-based compensation expense 397 382 8,789 - - - - (9,568)
Acquisition-related costs - - 99 - - - - (99)
Fair value adjustments to acquisition-related contingent consideration - - 2,345 - - - - (2,345)
Costs associated with potential business dispositions - - 128 - - - - (128)
Impairment and (gain) loss on disposition, net - - - - - - - -
Amortization - Unconsolidated Subs - - - - - - 51 (51)
Audit and legal fees related to on-going governmental investigations - - 12,474 - 7,663 - - (20,137)
Abbott transaction related expenses - - 26,079 - - - - (26,079)
Income tax effects on items above - - - - - 10,861 - (10,861)
Total of Supplemental Information $10,037 $2,299 $75,355 $ - $7,663 $10,861 $51 $(106,266)
================================= ======= ====== ======= ====================== ====== ======= === =========
Impact of above items on EPS numerator $ -
Impact of above items on EPS denominator (1,459)
1) All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".
Six months ended June 30, 2017
------------------------------
Cost of Net Research and Selling, General Impairment, Interest and other income, net Provision for Equity earnings of Net Income(1)
Revenue Development & net of loss on income taxes unconsolidated entities,
Administrative disposition net of tax
---
Amortization of acquisition-related intangible assets $22,159 $2,853 $47,535 $ - $ - $ - $ - $(72,547)
Restructuring charges 1,811 114 3,753 - - - - (5,678)
Impairment Charges - 25 - - - - - (25)
Stock-based compensation expense 793 766 18,372 - - - - (19,932)
Acquisition-related costs - - 151 - - - - (151)
Fair value adjustments to acquisition-related contingent consideration - - 2,833 - - - - (2,833)
Costs associated with potential business dispositions - - 185 - - - - (185)
Impairment and (gain) loss on disposition, net - - - - - - (229) 229
Amortization - Unconsolidated Subs - - - - - - 100 (100)
Audit and legal fees related to on-going governmental investigations - - 22,614 - 9,780 - - (32,393)
Abbott transaction related expenses - - 67,478 - - - - (67,478)
INRatio recall expense (2,549) - - - - - - 2,549
Legal settlement accrual - - - - - - - -
Income tax effects on items above - - - - - 14,383 - (14,383)
Total of Supplemental Information $22,214 $3,759 $162,922 $ - $9,780 $14,383 $(129) $(212,929)
================================= ======= ====== ======== ====================== ====== ======= ===== =========
Impact of above items on EPS numerator $ -
Impact of above items on EPS denominator (862)
1) All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".
View original content:http://www.prnewswire.com/news-releases/alere-reports-second-quarter-2017-financial-results-300499010.html
SOURCE Alere Inc.
